- Home
- SDST vs QNCX Comparison
SDST vs QNCX Comparison
Compare SDST & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDST | QNCX |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 19.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SDST | QNCX |
|---|---|---|
| Price | $1.72 | $0.95 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 140.7K | ★ 1.4M |
| Earning Date | 05-14-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.08 |
| 52 Week High | $7.67 | $4.55 |
Technical Indicators
Market Signals| Indicator | SDST | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 39.99 |
| Support Level | $0.28 | $0.79 |
| Resistance Level | $2.85 | $0.98 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 6.67 | 0.56 |
Price Performance
Historical ComparisonAbout SDST Stardust Power Inc.
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.